ArticleJournal of tissue engineering
Amelioration of intervertebral disc degeneration using engineered extracellular vesicle-delivered ZDHHC5 via inhibiting PANoptosis.
Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MSC-EVs in Cartilage Regeneration and Immunomodulation: Mechanisms and Therapeutic Prospects for Osteoarthritis, Rheumatoid Arthritis and Intervertebral Disc Degeneration.International journal of molecular sciences · 2026Review
- Programmed cell death in degenerative skeletal diseases: molecular crosstalk and combinatorial therapeutic strategies.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IDD) is a common condition and a leading cause of chronic low back pain, affecting millions of individuals worldwide. Human Umbilical Cord Mesenchymal Stromal Cell (hUCMSC)-derived extracellular vesicles (EVs) are emerging as a promising therapeutic strategy for IDD. However, the limited production yield and unclear mechanisms by which EV contents mediate their therapeutic effects have hindered the clinical application of EVs. In this study, using transcriptomic data and single-cell RNA sequencing, we identify PANoptosis as a key mechanism driving the progression of IDD. Furthermore, parathyroid hormone (PTH) enhances the secretion of hUCMSC-derived EVs and alters their cargo composition, which may contribute to their improved therapeutic effects. Mechanistically, PTH-preconditioned EVs, enriched with ZDHHC5, ameliorate PANoptosis by modulating ZBP1 transcription through competitive inhibition of YBX1 phosphorylation via palmitoylation. Our findings provide strong support for a cell-free therapeutic strategy utilizing EVs from PTH-preconditioned MSCs for IDD treatment and propose the ZDHHC5/YBX1/ZBP1 axis as a novel molecular target for inhibiting PANoptosis, thus paving the way for clinical translation and broader healthcare applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.